Cipla jumps on getting final approval for Arformoterol Tartrate Inhalation Solution

23 Jun 2021 Evaluate

Cipla is currently trading at Rs. 961.35, up by 5.70 points or 0.60% from its previous closing of Rs. 955.65 on the BSE.

The scrip opened at Rs. 955.65 and has touched a high and low of Rs. 965.80 and Rs. 955.65 respectively. So far 616965 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 982.05 on 11-Jun-2021 and a 52 week low of Rs. 621.50 on 01-Jul-2020.

Last one week high and low of the scrip stood at Rs. 967.45 and Rs. 943.50 respectively. The current market cap of the company is Rs. 77655.10 crore.

The promoters holding in the company stood at 36.73%, while Institutions and Non-Institutions held 40.43% and 22.84% respectively.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA). Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1491.40 -3.00 (-0.20%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×